Eric Vajda is Vice President, Preclinical Research and Development at OmniAb. Dr. Vajda has more than 20 years of biopharma experience in pharmacology and preclinical development. Prior to OmniAb, Dr. Vajda was VP of Preclinical R&D at Ligand Pharmaceuticals. From 2002-2022, Dr. Vajda had leadership roles in multiple research projects at Ligand including the Selective Androgen Receptor Modulator (SARM) program, Interleukin-1 Receptor Associated Kinase 4 (IRAK4) program, and Glucagon Receptor Antagonist program. Prior to Ligand, Dr. Vajda was a Sr. Research Scientist at Bayer Corporation in the osteoporosis and cancer research. Dr. Vajda has served as a reviewer for multiple scientific journals and has authored more than 50 scientific publications and presentations. Dr. Vajda earned a BS from Yale University and PhD in Bioengineering from the University of Utah, and also held a research fellowship position at the Klinik Wilhelm Schulthess in Zürich, Switzerland and completed postdoctoral research in the Division of Radiobiology at the University of Utah.
